127 Results for "

CBP/P300

" in MedChemExpress (MCE) Product Catalog:
Products (127)

127 Results for "CBP/P300" in MCE Product Catalog:

Cat. No.: HY-136285
CAS No.: 2374971-81-8
Purity:  99.74%
Research Areas:  

Cancer

CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
loading...
    loading...
Cat. No.: HY-128875
CAS No.: 2259641-71-7
Purity:  98.69%
Research Areas:  

Cancer

CBP/p300-IN-10 is a highly potent histone acetyltransferase EP300 and CREBBP with IC50 values of 26 nM and 39 nM, respectively. CBP/p300-IN-10 can be used to research anticancer .
loading...
    loading...
Cat. No.: HY-141546
CAS No.: 2304372-79-8
Research Areas:  

Cancer

Pocenbrodib is a P300/CBP inhibitor. Pocenbrodib blocks the function of P300/CBP and inhibits the acetylation of histones and non-histone proteins. Pocenbrodib may be used in research related to castration-resistant prostate cancer and other cancers .
loading...
    loading...
Cat. No.: HY-128876
CAS No.: 2299226-01-8
Purity:  98.95%
Research Areas:  

Cancer

CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1 .
loading...
    loading...
Cat. No.: HY-111420
CAS No.: 2443789-32-8
Purity:  99.71%
CBP/p300-IN-1 is a CBP/EP300 bromodomain inhibitor.
loading...
    loading...
Cat. No.: HY-161369
CAS No.: 2832961-58-5
Research Areas:  

Cancer

CBPD-268 is a potent and orally active CBP/p300 PROTAC degrader with an DC50 value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer .
loading...
    loading...
Cat. No.: HY-P10238
Target:  

Apoptosis

Research Areas:  

Cancer

MYBMIM is an inhibitor for assembly of the molecular MYB:CBP/P300 complex. MYBMIM inhibits growth of leukemia cells .
loading...
    loading...
Cat. No.: HY-154984
CAS No.: 3033714-58-5
Purity:  98.07%
Research Areas:  

Cancer

JET-209 is a potent CBP/p300 PROTAC degrader, with DC50 values of 0.05 nM and 0.2 nM for CBP and p300. JET-209 demonstrates remarkable anti-tumor activity against various acute leukemia cell lines and effectively inhibits tumor growth in xenograft tumor models. JET-209 can be used for the study of acute leukemia .
loading...
    loading...
Cat. No.: HY-134591
CAS No.: 2412056-48-3
Purity:  98.55%
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate which can be used for synthesizing dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .
loading...
    loading...
Cat. No.: HY-173552
CAS No.: 3067681-36-8
Synonyms: KAT-TCIP
Research Areas:  

Cancer

TCIP3 is a bivalent molecular glue degrader that binds dually to p300/CBP and BCL6. TCIP3 redirects p300 and CBP, thereby activating programmed cell death genes that are normally repressed by the oncogenic driver gene BCL6. TCIP3 induces acetylation of BCL6 and histone tails, inhibits c-MYC transcription. TCIP3 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .
loading...
    loading...
Cat. No.: HY-115539
CAS No.: 19881-70-0
Purity:  99.75%
Research Areas:  

Cancer

Windorphen is a Wnt/β-catenin signal inhibitor that specifically targets the function of the c-terminal transactivation domain of β-catenin-1 but not β-catenin-2. Windorphen selectively targets p300, disrupting the association of the mammalian β-catenin with p300 but not CBP .
loading...
    loading...
Cat. No.: HY-112359
CAS No.: 1422253-37-9
Target:  

β-catenin Wnt

Research Areas:  

Cancer

C-82 is a second-generation specific CBP/β-catenin antagonist, which inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300 .
loading...
    loading...
Cat. No.: HY-134592
CAS No.: 1936431-36-5
Purity:  98.48%
Research Areas:  

Cancer

Piperidine-GNE-049-N-Boc is a ligand for target protein for PROTAC of dCBP-1 (HY-134582). dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .
loading...
    loading...
Cat. No.: HY-139148
CAS No.: 2266569-73-5
Purity:  99.28%
UMB298 is a potent and selective CBP/P300 bromodomain inhibitor .
loading...
    loading...
Cat. No.: HY-161483
CAS No.: 1936425-34-1
Research Areas:  

Cancer

CBP/p300 ligand 3 (conpound 3) is a CBP/p300 bromodomain ligand that binds to the CBP and p300 bromodomains with IC50 values ​​of 1.1 nM and 1.3 nM, respectively. CBP/p300 ligand 3 can be used to synthesize CBPD-268 (HY-161369) .
loading...
    loading...
Cat. No.: HY-147261
CAS No.: 2379416-48-3
Research Areas:  

Cancer

B026 is a selective, potent, orally active p300/CBP histone acetyltransferase (HAT) inhibitor with IC50 values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines .
loading...
    loading...
Cat. No.: HY-162259
CAS No.: 3032646-96-8
Research Areas:  

Cancer

QC-182 is a p300/CBP PROTAC degrader with a DC50 of 93 nM against p300. QC-182 induces ubiquitination and proteasomal degradation of p300 and CBP in a CRBN-dependent manner. QC-182 induces Apoptosis. QC-182 exhibits anticancer activity against liver cancer cells. QC-182 can be used for the research of hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-139707
CAS No.: 2484739-21-9
Purity:  98.55%
Synonyms: Thalidomide-NH-CBP/P300 ligand 2
Research Areas:  

Cancer

PROTAC CBP/P300 Degrader-3 (Thalidomide-NH-CBP/p300 ligand 2) is a PROTAC degrader of CBP and p300. PROTAC CBP/P300 Degrader-3 promotes ubiquitination and degradation of CBP/P300. It can be used in the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-100132
CAS No.: 1889284-33-6
Research Areas:  

Cancer

P300/CBP-IN-5 is a potent p300/CBP histone acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC50 of 18.8 nM .
loading...
    loading...
Cat. No.: HY-123009
CAS No.: 927823-01-6
KCN1 is a p300/HIF-1α interaction inhibitor with a Kd value of 345 nM for p300-CH1. KCN1 binds to the CH1 domain of p300, blocks the assembly of the p300/HIF-1α complex, and disrupts the HIF-1α-p300/CBP interaction. KCN1 inhibits cancer cell growth, induces cancer cell cycle arrest and apoptosis. KCN1 inhibits β-galactosidase activity and downregulates the expression of VEGF, Glut1, CA9 and CAIX. KCN1 exerts anticancer activity in mouse tumor xenograft models. KCN1 can be used in research related to malignant glioma, pancreatic cancer and metastatic uveal melanoma .
loading...
    loading...